Skip to content

European Psychiatry

ISSN 0924-9338, 1778-3585

289 papers in the library · 617 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Elektra complex in dissociative identity disorder: A case report

European Psychiatry April 1, 2021 Pushpendra Kumar Jain, Varchasvi Mudgal, Ujwal Sardesai et al.

Introduction Dissociative identity disorder is a quite popular psychiatric diagnosis in general public but in actuality has a very low prevalence rate. Dissociative identity disorders are characterized by disruption of identity characterized by two or more distinct personality states with its own memories, behaviour, and preferences. Objectives Authors present a case report about a patient of...

DOI: 10.1192/j.eurpsy.2021.1815 (opens in new tab) Full text (opens in new tab) Dissociative identity disorder Borderline personality disorder Psychotherapist Dissociative disorders +4

Treating with esketamine nasal, will increase blood pressure?

European Psychiatry April 1, 2021 V. Rosello-Molina, F.J. Castells Pons, V. Avellon Juarez et al.

Introduction Esketamine had been rised as a potential treatment for Resistant Depression, becoming an alternative for the use of Electroconvulsive Therapy. In Spain since 2020, it has been applied for compassionate use but is not widely used. Although Esketamine is defined safe and effective in preliminary studies, there are common side effects which could reduce it use. Objectives Increasing...

Is ketamine and lamotrigine interactions responsible for the sub-therapeutic effect of ketamine?

European Psychiatry April 1, 2021 Mahwish Adnan, F. Motiwala, Zeeshan Mansuri et al.

Introduction The immediate antidepressant effect of Ketamine has become a breakthrough in the treatment of depression. Cytochrome CYP3A4 and 2B6 primarily metabolize Ketamine. Objectives The present study explores potential pharmacokinetic and pharmacodynamic interactions of Lamotrigine and Ketamine. Methods A literature search was conducted using (“ketamine” OR “Lamotrigine” AND Interactions...

I-mindfulness-based cognitive therapy (i-MBCT) in the treatment of COVID-19 related adjustment disorder. a RCT study with active control group

European Psychiatry April 1, 2021 Paweł Holas

Introduction Adjustment disorder (AD) is described as a maladaptive reaction to an identifiable psychosocial stressor/s that usually emerges within a month after the onset of the stressor. With all uncertainty, fears and disorientation, it’s no surprise that many people have developed an AD linked to the sudden changes brought about by COVID-19, such as threat to life, imposed restrictions, and...

Therapeutic use of psychedelic drugs in depression disorders

European Psychiatry April 1, 2021 M. Trigo

Introduction Depression is one of the most prevalent mental illnesses, leading to important personal distress and economic consequences. Treatment is long, often involving psychotherapy and pharmacological treatment, and relapses are frequent. Used mostly for treatment of mood disorders and alcohol dependence, drugs such as lysergic acid diethylamide (LSD) were studied in the 1950’s and showed...

“I have no disease and weed just relaxes me!”: The therapeutic challenge in young patients with psychosis and cannabis abuse

European Psychiatry April 1, 2021 P. Mota

Introduction Substance use disorders (SUDs) are estimated to affect around 30 million people worldwide, and are characterized by repeated use of a substance that leads to clinically significant impairment or suffering, making it a serious health problem, with high associated costs. Objectives Understand and evaluate the impact of cannabis use on adherence to treatment in young patients with...

Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning

European Psychiatry 2020 Teresa Sánchez‐Gutiérrez, Belén Fernández‐Castilla, Sara Barbeito et al. 27 citations

BACKGROUND: The implications of cannabis use in the onset of early psychosis and the severity of psychotic symptoms have resulted in a proliferation of studies on this issue. However, few have examined the effects of cannabis use on the cognitive symptoms of psychosis (i.e., neurocognitive functioning) in patients with first-episode psychosis (FEP). This systematic review and meta-analysis aim...

Early onset of cannabis use and violent behavior in psychosis

European Psychiatry 2020 Valérie M. Moulin, Luis Alameda, David Framorando et al. 22 citations

BACKGROUND: Although evidence from psychosis patients demonstrates the adverse effects of cannabis use (CU) at a young age and that the rate of CU is high in subgroups of young violent patients with psychotic disorders, little is known about the possible effect of the age of onset of CU on later violent behaviors (VB). So, we aimed to explore the impact of age at onset of CU on the risk of...

A new “inside-out” perspective on general factor p

European Psychiatry August 5, 2019 Thomas M. Kelley, William F. Pettit, Jack Pransky et al. 6 citations

This theoretical article revives a classical bridging construct, canalization, to describe a new model of a general factor of psychopathology. To achieve this, we have distinguished between two types of plasticity, an early one that we call 'TEMP' for 'Temperature or Entropy Mediated Plasticity', and another, we call 'canalization', which is close to Hebbian plasticity. These two forms of...

DOI: 10.1016/j.eurpsy.2019.06.009 (opens in new tab) Variance accounting Psychopathology Plasticity Hebbian theory +6

What are sweet dreams made of? Analysis of psychoactive substances into “gummies”: A retrospective descriptive study

European Psychiatry April 1, 2017 Amira Trabsa, E. Monteagudo, D.d. Mariona et al. 2 citations

Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...

The impact of Cannabis in Schizophrenia: Pafip Three-year Longitudinal Study on Outcome and Functionality After a First Episode of Psychosis

European Psychiatry April 1, 2017 M. Gomez Revuelta, María Juncal Ruiz, O. Porta Olivares et al.

Introduction The association between cannabis and psychosis makes crucial the intervention on cannabis use disorder at first episodes of psychosis (FEP), especially among young population. In this group of patients, the harmful potential of cannabis is more evident by its influence on neurodevelopment. However, the nature of the association cannabis-psychosis is not clearly described. It seems...

Alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report

European Psychiatry April 1, 2017 Lucie Bartova, Ana Weidenauer, Markus Dold et al.

IntroductionTreatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant...

The effectiveness of mindfulness-based stress reduction (MBSR) in anxiety and depression in patients with multiple sclerosis (MS)

European Psychiatry April 1, 2017 E. Alisaleh, S. Ghahari

ObjectiveThe main objective of the present study is to investigate effectiveness of mindfulness-based stress reduction in anxiety and depression in patients with multiple sclerosis.MethodsThis study is in kind of semi-experimental research in form of pretest–posttest pattern with control group. Statistical population of the study consists of all patients with multiple sclerosis referred to Iran...

Intramuscular ketamine in depression, suicidal thoughts and anxiety: A report on two cases

European Psychiatry April 1, 2017 M. Cigognini, R. Moreno

Introduction: Several studies have shown that ketamine, an antagonist of NMDA receptors, represents a promising alternative in the treatment of depression. The therapeutic use of ketamine, commonly used at a dose of 0.5 mg/kg, and in a single application IV has been short and requires monitoring in a hospital setting. IM use has been shown to be effective in treating depression and suicide...

Comparative examination of the differences between cannabis psychosis and methamphetamine psychosis in a psychological state

European Psychiatry April 1, 2017 A. Oda

BackgroundWith the rapid and intensive spread of marihuana abuse among youth, Japanese society is focusing on law enforcement against drug abusers. In 2016, a mass killing allegedly committed by a marihuana abuser was reported in Japan.ObjectivesTo consider that common recognition of the diverse process and potential risks of cannabis psychosis should be shared among psychiatrists.AimsElicit...

25c-nbome: Case report and literature review

European Psychiatry April 1, 2017 M. Preve, S. Casigliani, L. Tognola et al.

IntroductionNovel psychoactive drugs (NPS) have rapidly increase in the last years in the drug market as a recreational use. A new group of toxic phenethylamine derivates named NBOMe of 2 C class present have emerged recently, are frequently bought using the internet and have similar effects to other hallucinogenic drugs; however, they may pose larger risks, due to the limited knowledge about...

Clinical predictors of antidepressant response to ketamine in unipolar treatment-resistant depression

European Psychiatry April 1, 2017 L.C. Del Sant, E. Magalhães, Ana C. Lucchese et al.

Introduction: The non-competitive N-methyl-d-aspartate glutamate receptor antagonist ketamine has been shown to have rapid antidepressant effects in treatment-resistant depression (TRD). However, only a few studies have investigated which clinical characteristics predict a response to ketamine. Objectives: To assess sociodemographic variables and clinical markers that predict response to...

Performance of cognitive measures and affective ranges in clients marked with spirit possession in Oman

European Psychiatry April 1, 2017 S. Musharrafi, Y. Al-Kalbani, S. Al-Adawi

Background: There is a dearth of studies that have explored cognitive performance in different grades of spirit possession. Aim: This study was undertaken to investigate two areas: the first was to explore whether there is a difference in demographic characteristics among presently defined grades of spirit possession in Oman: total possession (TP), partial possession (PP) and symbiotic...

Psychosis – Different presentation for designer drugs compared to cannabis abusers?

European Psychiatry April 1, 2017 F. Dumitrescu

Introduction: “Bath salts” target the endocannabinoid system in a similar manner to cannabis. In the case of designer drug misuse, subjects seem to be at higher risk of psychotic symptoms. Aims: To investigate the nature and frequency of psychotic symptoms associated with cannabis and/or bath salts misuse in a male inpatient population. Method: The files of 107 patients admitted to the...

Adult ADHD and the use of mindfulness-based practice: A pilot study

European Psychiatry April 1, 2017 A. Allen, R. Ansari, J. Thurley et al.

Educational objectives: The goal of this poster is to discuss a brief pilot study in which mindfulness – and yoga-based practices were utilized with a group of adult ADHD patients. Methods: A sample of 10 adults participated in a pilot group which utilized the use mindfulness-based and yoga practices to address ADHD. This group was a single 2 hour session which was a pilot for a future 6-week...

The effect of mindfulness group therapy on a broad range of psychiatric symptoms: A randomised controlled trial in primary health care

European Psychiatry February 8, 2017 Jan Sundquist, Karolina Palmér, Lars-Åke Johansson et al. 40 citations

BACKGROUND: The need for psychotherapy in primary health care is on the increase but individual-based treatment is costly. The main aim of this randomised controlled trial (RCT) was to compare the effect of mindfulness-based group therapy (MGT) with treatment as usual (TAU), mainly individual-based cognitive behavioural therapy (CBT), on a broad range of psychiatric symptoms in primary care...

Shall we really say goodbye to first rank symptoms?

European Psychiatry July 17, 2016 Andreas Heinz, Martin Voss, Stephen M. Lawrie et al. 84 citations

BACKGROUND: First rank symptoms (FRS) of schizophrenia have been used for decades for diagnostic purposes. In the new version of the DSM-5, the American Psychiatric Association (APA) has abolished any further reference to FRS of schizophrenia and treats them like any other "criterion A" symptom (e.g. any kind of hallucination or delusion) with regard to their diagnostic implication. The ICD-10...

The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)

European Psychiatry March 1, 2016 Laura Orsolini, Alessandro Valchera, Duccio Papanti et al. 3 citations

Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, including cannabis, MDMA (methylenedioxymethamphetamine), psilocybin, mescaline and other psychostimulants....

Newer substances and their effects: A case report

European Psychiatry March 1, 2016 Inmaculada Peñuelas‐calvo, J. Sevilla Llewellyn-Jones, Aditya Sareen et al. 1 citation

Introduction Due to constant flow of people in and out of Europe several drugs are now days appearing in European markets that were previously unknown. There is a need to gain awareness and knowledge about these new substances and to recognize their use and learn about their effects and management. Aims/objectives Ayahuascais commonly called yagé is a traditional spiritual medicine in...

Treatment of heroin dependence with ibogaine

European Psychiatry March 1, 2016 Arnt Schellekens, Toon Van Oosteren, Thomas Knuijver et al. 1 citation

Background The use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates....

DOI: 10.1016/j.eurpsy.2016.01.799 (opens in new tab) Opiate Pharmacology Hallucinogen Heroin +1